Cosmetic & other
Topical cosmetic peptides and entries that do not fit a single physiological system.
Questions
What does the Cosmetic and other category cover?
The sampled monographs range from cosmetic ingredients acetyl hexapeptide-8 and palmitoyl pentapeptide-4 to the medicine glatiramer acetate, the immunosuppressant cyclosporine, and the diagnostic macimorelin. The atlas includes boundary cases explicitly rather than assuming every entry is one defined peptide.
Are cosmetic ingredients in this category approved drugs?
No. Acetyl hexapeptide-8 and palmitoyl pentapeptide-4 are described as cosmetic ingredients, not approved drugs. An EU CosIng inventory entry is not a regulatory authorization or safety approval. Their monographs distinguish cosmetic status from the pharmaceutical approvals documented for other sampled entries.
How strong is the wrinkle evidence for the sampled cosmetic peptides?
The acetyl hexapeptide-8 and palmitoyl pentapeptide-4 monographs describe modest wrinkle findings from small, mainly manufacturer-sponsored studies, with limited independent clinical evidence. This does not support treating cosmetic marketing claims as equivalent to evidence for an approved medical indication.
Why are glatiramer acetate and macimorelin peptide-atlas boundary cases?
Glatiramer acetate is a heterogeneous polypeptide mixture without one defined sequence. Macimorelin is a peptidomimetic that mimics ghrelin but is not a conventional peptide. Their monographs include them as explicit boundary cases, consistent with the atlas scope methodology.
What separates cyclosporine from the cosmetic entries in this group?
Cyclosporine is an approved cyclic-peptide medicine with documented transplant, autoimmune, and ophthalmic indications. The sampled cosmetic peptides are ingredients with limited cosmetic-trial evidence and no pharmaceutical approval. Their shared navigation category does not imply comparable evidence, regulation, or use.
Join the atlas. Get the evidence updates.
Receive concise notes when peptide evidence, status, or source records change.